Rocket Lab's SpaceX Proxy Era Ends as Market Pivots to Neutron Execution

What happened

Rocket Lab lost roughly $25 billion in market value despite reporting record Q1 revenue of $200.3 million (up 63.5%) and a backlog that doubled to $2.2 billion, indicating a market reassessment of the stock's risk-reward. The Seeking Alpha article argues the 'SpaceX proxy' narrative that had inflated the stock is ending, as investors now demand tangible progress on Neutron and conversion of backlog into profit rather than just contract wins. While operational momentum is strong—Electron cadence is steady and Neutron could generate $1.0–$1.1 billion annually under a 20-launch scenario—the stock's valuation at $110 per share still prices in smooth execution and zero margin for error. The DeepValue Master Report maintains a WAIT rating, citing the need for observable checkpoints: Q2 revenue guidance of $225–$240 million, Neutron timeline language staying anchored to Q4 2026, and initial HASTE launch activity under the MACH-TB 2.0 contract. The combination of a crowded sentiment, insider selling in late May, and negative earnings (Q1 operating loss of $56 million) leaves the stock vulnerable to any timeline slip or backlog deterioration, reinforcing the case for patience.

Implication

In the near term, the market's shift from a speculative 'SpaceX proxy' to an execution-driven thesis means RKLB will be judged on hard deliverables rather than contract momentum. Over the next six months, the key catalysts are: (1) Q2 revenue delivery within the $225–$240 million guide, (2) consistent Neutron timeline language in the next 10-Q, and (3) visible HASTE launch scheduling from the MACH-TB 2.0 contract. Without these, the stock could re-rate lower toward the $80 attractive entry level identified in the DeepValue report. The recent $25 billion market cap loss likely reflects this repricing as the market removes the SpaceX proxy premium. Long-term investors should use any weakness from Neutron slips as a buying opportunity, but only after tangible progress is confirmed. The insider selling cluster in late May adds a cautionary note, suggesting even management is taking profits at these levels.

Thesis delta

The core thesis shifts from 'SpaceX proxy' to 'execution compounder,' meaning the stock's upside now depends on demonstrated operational milestones rather than narrative expansion. The recent selloff confirms that the premium for being a SpaceX alternative has deflated, and the next 3–6 months will test whether Rocket Lab can convert its record backlog into profits without major schedule or penalty surprises. Investors must treat Neutron's Q4 2026 target as the make-or-break catalyst, as any delay would remove the remaining valuation support.